Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 17

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 17
---
 the U.S. Food and Drug Administration, including the prostate cancer drug, Erleada ®. Since 2019, Dr. Heyman has served as a Venture Partner for Arch Ventures, a venture capital firm. Dr. Heyman is also Vice Chair of the Board of Trustees at the Salk Institute for Biological Studies and serves on the Board Foundation for the American Association for Cancer Research and on the board at the University of California at San Diego (“UCSD”) Moores Cancer Center. Previously, Dr. Heyman served on the board of directors of Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, Metacrine, Inc. (formerly Nasdaq: MTCR), a clinical-stage biopharmaceutical company, and Yumanity Therapeutics, Inc. (Nasdaq: YMTX), a biotechnology company. Dr. Heyman has won numerous awards, including the Ernst and Young San Diego Regional Entrepreneur of the Year, the Connect Hall of Fame Award, the Endocrine Society Outstanding Innovation Award and the UCSD Rell Sunn Award. Dr. Heyman received a B.S. in Chemistry from the University of Connecticut and a Ph.D. in Pharmacology from the University of Minnesota. We believe that Dr. Heyman is qualified to serve on our board of directors because of his perspective having served as both an executive and director of similar corporations, including public companies, his scientific background, and his extensive career in the biotechnology industry. Laurie Stelzer has served as a member of our board of directors since August 2020. Since January 2025, Ms. Stelzer has served as the Chief Financial officer of Kailera Therapeutics, Inc. a clinical-stage biopharmaceutical company. Ms. Stelzer previously served as the Chief Financial Officer of Orna Therapeutics, a 9

TABLE OF CONTENTS

biotechnology company, from May 2024 until January 2025. From September 2023 until May 2024, she served as the Chief Financial Officer of ReNAgade Therapeutics, Inc., a biotechnology company, until its acquisition by Orna Therapeutics. She previously served as the Chief Financial Officer of Mirati from May 2022 until September 2023. Ms. Stelzer formerly served as Executive Vice President and Chief Financial Officer of Arena Pharmaceuticals, Inc. (acquired by Pfizer) from March 2020 until the completion of Pfizer’s acquisition in March